Azacitidine Use in MDS and AML Patients: Best Selection for Better Results
Mauricette Michallet(Université Claude Bernard Lyon 1), Fiorenza Barraco(Hôpital Lyon Sud), Sophie Ducastelle(Hôpital Lyon Sud), Marie Y. Detrait(Hôpital Civil de Charleroi), Stéphane Morisset(Lyon 1 Université), Catherine Rioufol(Lyon 1 Université), Youcef Chelghoum(Hôpital Edouard Herriot), Xavier Thomas(Hôpital Lyon Sud), Carine Champigneulle(Hôpital Lyon Sud), Franck E. Nicolini(Université Claude Bernard Lyon 1), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Eric Wattel(Université Claude Bernard Lyon 1), Florence Ranchon(Lyon 1 Université), Mohamad Sobh(Ottawa Hospital), Caroline Le Jeune(Hospices Civils de Lyon)
Cited by 0
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
|Journal of Clinical Oncology|2003|606
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
|Blood|1994|581
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547